FeesSafety
Pluang+

Bitcoin nears $72,500 buy zone as resistance holds at $82,000 amid mixed liquidation signals.

Technical Signals
26 Oct 2026
Blockonomi
View Source
Bearish
Bitcoin nears $72,500 buy zone as resistance holds at $82,000 amid mixed liquidation signals.

Bitcoin is trading around $79,757, down 0.74% daily and 3.22% weekly, with analyst Ali Charts highlighting a potential buying zone at $72,500 following a breakdown below a rising channel. Resistance remains strong at $82,000, which could limit upward moves unless broken, possibly triggering short liquidations and a price squeeze. Liquidation heatmaps show clusters near $81,500-$82,000 on the upside and $78,500-$79,000 on the downside, indicating uncertainty with key levels at $81,000 to reclaim for bulls and $79,000 to defend for downside risk. The $72,500 level is seen as a potential entry point if the correction continues, but it is not yet confirmed as a reversal point.

Bitcoin price risks a slide to $72,500 as resistance at $82,000 caps recovery, providing context for cryptocurrency market activity. For readers following digital assets, here is Pluang's market snapshot as of Oct 26, 2026 15:02 WIB: out of 50 major cryptocurrencies priced on Pluang, 9 rose and 40 fell today. Notable movers include FIL (Filecoin) at Rp16.209 with a 1-day change of -3.35% and Pluang order activity showing 67% Sell / 33% Buy, XTZ (Tezos) at Rp5.079 down 3.26% with 46% Sell / 54% Buy, and COTI at Rp186 down 3.04% with 53% Sell / 47% Buy. Typical hold times range from 100 to 122 days among these assets.

More News

Corxel US to go public via merger with Amanat Acquisition, raising $377M to advance oral obesity drugs.

Corxel US to go public via merger with Amanat Acquisition, raising $377M to advance oral obesity drugs.

Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...

Company Fundamentals
Bullish
59 minutes ago
EIK1001 combo shows strong response in advanced lung cancer with good safety, advancing to Phase 2/3 trial.

EIK1001 combo shows strong response in advanced lung cancer with good safety, advancing to Phase 2/3 trial.

Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...

Company Fundamentals
Bullish
59 minutes ago
Microsoft, Alphabet, and Amazon, 15% of S&P 500, report earnings within 2 days.

Microsoft, Alphabet, and Amazon, 15% of S&P 500, report earnings within 2 days.

Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...

Company Fundamentals
Neutral
1 hour ago
Conow launches Atlas 6000 AC, a 6kWh AI-powered home battery for solar upgrades in Germany.

Conow launches Atlas 6000 AC, a 6kWh AI-powered home battery for solar upgrades in Germany.

Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...

Others
Bullish
1 hour ago
Phase-3 study shows Trastuzumab Pamirtecan improves progression-free survival in HR+/HER2-low metastatic breast cancer.

Phase-3 study shows Trastuzumab Pamirtecan improves progression-free survival in HR+/HER2-low metastatic breast cancer.

BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App